NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
271 Blekinge |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 25 | 0.8% | 4 | 0.1% | . | . | . | . | . | . | . | . | 3196 | 99.1% | 3225 | 100.0% |
ASCUS | 26 | 10.9% | 42 | 17.6% | 23 | 9.6% | . | . | . | . | 1 | 0.4% | 147 | 61.5% | 239 | 100.0% |
LSIL | 26 | 13.4% | 66 | 34.0% | 37 | 19.1% | . | . | 2 | 1.0% | 1 | 0.5% | 62 | 32.0% | 194 | 100.0% |
Atypical glandular cells/AGC | 1 | 12.5% | . | . | 2 | 25.0% | 1 | 12.5% | 2 | 25.0% | . | . | 2 | 25.0% | 8 | 100.0% |
Unclear atypia | . | . | . | . | 1 | 50.0% | . | . | . | . | . | . | 1 | 50.0% | 2 | 100.0% |
ASC-H | 1 | 4.0% | 6 | 24.0% | 18 | 72.0% | . | . | . | . | . | . | . | . | 25 | 100.0% |
HSIL | . | . | 5 | 13.9% | 29 | 80.6% | 1 | 2.8% | 1 | 2.8% | . | . | . | . | 36 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | 2 | 100.0% | . | . | . | . | . | . | 2 | 100.0% |
Totalt | 79 | 2.1% | 123 | 3.3% | 110 | 2.9% | 4 | 0.1% | 5 | 0.1% | 2 | 0.1% | 3408 | 91.3% | 3731 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |